Screener
Allogene Therapeutics ALLO EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's EBITDA?
- Allogene Therapeutics (ALLO) reported EBITDA of -$43.22M in Q1 2026.
- How has Allogene Therapeutics's EBITDA changed year-over-year?
- Allogene Therapeutics's EBITDA increased by 30.4% year-over-year, from -$62.09M to -$43.22M.
- What is the long-term trend for Allogene Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Allogene Therapeutics's EBITDA has grown at a 3.5% compound annual growth rate (CAGR), from -$171.45M to -$196.96M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Allogene Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude